FDAnews
www.fdanews.com/articles/188005-uk-brexit-implementation-period-would-mean-business-as-usual

UK Brexit Implementation Period Would Mean Business As Usual

August 13, 2018

The UK’s Medicines and Healthcare products Regulatory Agency released guidance on how EU mutual recognition agreements would affect devicemakers during the Brexit implementation period.

For the purposes of international agreements, the UK will be treated as an EU member state during the implementation period and there will be no disruption to existing relationships, the MHRA said.

During the proposed implementation periods, CE marking would continue to be used and recognized for both the UK and EU markets, and UK-based device manufacturers would not require an authorized representative based in the EU.

View today's stories